Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2024 Earnings Conference
The following is a summary of the Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript:Financial Performance:Summit Therapeutics ended Q1 2024 with a cash balance of $157 million, projecte
moomoo AIMay 2 06:33 ET · Conference Call
Express News | Summit Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results
BenzingaMay 1 10:26 ET
Correct: Summit Therapeutics 1Q Adj Loss/Shr 5c >SMMT
Correct: Summit Therapeutics 1Q Adj Loss/Shr 5c >SMMT
Dow JonesMay 1 07:06 ET
Express News | Summit Therapeutics Inc - Updated Guidance of Cash Runway for Operations Through Q1 2025
ReutersMay 1 07:03 ET
Express News | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
ReutersMay 1 07:00 ET
Express News | Summit Therapeutics Q1 EPS USD -0.06
ReutersMay 1 07:00 ET
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.
BusinesswireApr 24 16:30 ET
Summit Therapeutics Appoints Biotech Veteran to Board
TipRanksApr 11 16:52 ET
Express News | Summit Therapeutics Appoints DR. Mostafa Ronaghi, Renowned Executive and Genomicist, to Its Board of Directors
Moomoo 24/7Apr 11 16:30 ET
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to Its Board of Directors
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
BusinesswireApr 11 16:30 ET
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Summit Therapeutics (SMMT) and Neurocrine (NBIX)
TipRanksApr 11 07:30 ET
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chief Medical Officer, will participate in a fireside chat on behalf of our organization surrounding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday April 16, 2024 at 2:30pm ET.
BusinesswireApr 10 07:00 ET
UPDATE 2-Illumina CFO Goswami to Depart, Former Summit Therapeutics Exec Dhingra to Succeed
Yahoo FinanceApr 9 17:28 ET
Illumina Appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to...
PR NewswireApr 9 16:05 ET
Express News | Summit Therapeutics Shares Are Trading Lower After the Company Announced a Leadership Restructuring
Moomoo 24/7Apr 4 15:25 ET
Summit Therapeutics Appoints COO to Additional Role of CFO
Summit Therapeutics (SMMT) said in a Wednesday regulatory filing that Ankur Dhingra resigned as chief financial officer of the company on April 2. The company appointed Chief Operating Officer Manmeet
MT NewswiresApr 4 03:27 ET
Summit Therapeutics Announces Major Leadership Restructuring
TipRanksApr 3 16:52 ET
Express News | Summit Therapeutics' Ankur Dhingra Resigned As Chief Financial Officer Of Company; Appointed Its Chief Operating Officer Manmeet Soni To Office Of Chief Financial Officer
Moomoo 24/7Apr 3 16:47 ET
Insider Buys Additional US$411k In Summit Therapeutics Stock
Investors who take an interest in Summit Therapeutics Inc. (NASDAQ:SMMT) should definitely note that the Co-CEO, President & Director, Mahkam Zanganeh, recently paid US$3.73 per share to buy US$411k worth of the stock.
Simply Wall StMar 30 09:10 ET
Why Summit Therapeutics Stock Crushed the Market This Week
One exceptional stock in the healthcare sector this trading week was Summit Therapeutics (SMMT 10.40%).
The Motley FoolMar 29 17:43 ET
No Data
No Data